ArrowMark Colorado Holdings’s BioCryst Pharmaceuticals BCRX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-125,307	Closed	-$1.02M	–	311
2019 Q1	$1.02M	Hold	125,307	–	–	0.01%	274
2018 Q4	$1.01M	Buy	+125,307	New	+$974K	0.01%	291
2018 Q1	–	Sell	-12,019	Closed	-$59K	–	326
2017 Q4	$59K	Hold	12,019	–	–	﹤0.01%	331
2017 Q3	$63K	Hold	12,019	–	–	﹤0.01%	330
2017 Q2	$67K	Hold	12,019	–	–	﹤0.01%	315
2017 Q1	$101K	Buy	12,019 +1,181	+11%	+$8.21K	﹤0.01%	298
2016 Q4	$69K	Buy	10,838 +3,717	+52%	+$19.3K	﹤0.01%	293
2016 Q3	$31K	Buy	+7,121	New	+$28.4K	﹤0.01%	311

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

ArrowMark Colorado Holdings's BCRX Position: Q2 2019 in Review

ArrowMark Colorado Holdings sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 125,307 shares — an estimated $1.02M sold.

ArrowMark Colorado Holdings first reported a position in BCRX in Q3 2016 and held it in 8 quarters. The position peaked at $1.02M in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

ArrowMark Colorado Holdings reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
ArrowMark Colorado Holdings sold 125,307 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $1.02M.
ArrowMark Colorado Holdings first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 8 quarters.
ArrowMark Colorado Holdings's BioCryst Pharmaceuticals position peaked at $1.02M in Q1 2019.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2019, filed 14 Aug 2019.